4-Chloro-3-(Trifluoromethyl)phenyl Isocyanate CAS 327-78-6 Pite ≥99.0% Sorafenib Tosylate Entèmedyè Faktori
Pwovizyon Komèsyal Sorafenib Tosylate ak entèmedyè ki gen rapò:
Sorafenib Tosylate CAS: 475207-59-1
Sorafenib CAS: 284461-73-0
4-Chloro-N-Methyl-2-Pyridinecarboxamide CAS: 220000-87-3
4-(4-Aminophenoxy)-N-Methylpicolinamide CAS: 284462-37-9
4-Chloro-3-(Trifluoromethyl)phenyl Isocyanate CAS: 327-78-6
| Non | 4-Chloro-3-(Trifluoromethyl)phenyl Isocyanate |
| Sinonim | Asid Isosyanic 4-Chloro-3-(Trifluoromethyl)phenyl Ester |
| Nimewo CAS | 327-78-6 |
| Nimewo CAT | RF-PI167 |
| Estati Stock | Nan Stock, Pwodiksyon Echèl Jiska Tòn |
| Fòmil molekilè | C8H3ClF3NO |
| Pwa molekilè | 221.56 |
| Pwen k ap fonn | 37.0 ~ 42.0 ℃ (lit.) |
| Pwen bouyi | 86.0 ~ 90.0 ℃ 14 mmHg (limen) |
| Dansite | 1.4720 |
| Kondisyon Shipping | Anbyen |
| Mak | Ruifu Chimik |
| Atik | Espesifikasyon |
| Aparans | Crystalline blan |
| Pite / Metòd analiz | ≥99.0% (HPLC) |
| Idantifikasyon | (1) IR (2) HPLC |
| Imidite (KF) | ≤0.50% |
| Metal lou | ≤10ppm |
| Enpurte A | ≤0.15% |
| Enpurte B | ≤1.0% |
| Enpurte C | ≤1.0% |
| Lòt moun ki pa marye enpurte | ≤0.50% |
| Enpurte total | ≤1.0% |
| Solvans rezidyèl | Toluèn ≤0.089% |
| Tès Creole | Enterprise Standard |
| Itilizasyon | Entèmedyè Sorafenib Tosylate (CAS: 475207-59-1) |
Pake: Boutèy, sak papye aliminyòm, tanbou katon, 25kg / tanbou, oswa selon kondisyon kliyan an.
Kondisyon Depo:Sere nan resipyan ki fèmen nan yon kote ki fre ak sèk;Pwoteje kont limyè, imidite ak ensèk nuizib.
Manifakti ak pite segondè ak bon jan kalite ki estab
Pwovizyon komèsyal Sorafenib Tosylate (CAS: 475207-59-1) Entèmedyè ki gen rapò:
Sorafenib Tosylate CAS: 475207-59-1
Sorafenib CAS: 284461-73-0
4-Chloro-N-Methyl-2-Pyridinecarboxamide CAS: 220000-87-3
4-(4-Aminophenoxy)-N-Methylpicolinamide CAS: 284462-37-9
4-Chloro-3-(Trifluoromethyl)phenyl Isocyanate CAS: 327-78-6
Sorafenib Tosylate (CAS: 475207-59-1) se yon nouvo kalite dwòg anti-tumeur milti-sib, te devlope pa Alman Bayer Pharmaceuticals yo, epi li montre aktivite anti-tumeur awogan nan tès preklinik sou bèt.Sorafenib disponib nan tablèt 200 mg pou administrasyon oral epi li itilize nan tretman RCC ak HCC.Sorafenib Tosylate (CAS: 475207-59-1) ka afekte selil timè yo ak veso sangen timè yo.Li gen yon efè doub antitumoral: li ka bloke chemen transdiksyon siyal selil yo medyatè pa RAF/MEK/ERK dirèkteman anpeche kwasans selil timè, pandan y ap tou anpeche reseptè VEGF ak faktè kwasans ki sòti nan plakèt (PDGF) pou anpeche fòmasyon nouvo san timè. veso yo, kidonk endirèkteman anpeche kwasans selil timè yo.
